Matignon Launches Major New European Device Fund
This article was originally published in Start Up
Europe has a remarkable tradition of clinical thought leaders who develop major new medical device technologies. Yet European device company start-up activity lags far behind the rate of clinical breakthroughs. There are several reasons for this, including the dearth of European venture capital willing to back these start-ups. Matignon Technologies sees this gap in financing of European device start-ups as an opportunity, and has just launched one of the largest European funds dedicated primarily to medical technology.
You may also be interested in...
In 2006, the number of late-stage private equity deals in the medical device sector is up significantly from 2005. At the IN3 East medtech conference in October, a lively panel of venture capital investors from Galen Partners, 3i, Matignon Technologies and OrbiMed Advisors discussed why this is so, and the risks, benefits and models for late-stage investing.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.